Pharmacotherapy of prostatitis

Bibliography

• McNaughton-Collins M, Stafford RS, O'Leary MP, How common is prostatitis? A national survey of physician visits. J Urol 1998;159:1224-8
   PubMed Web of Science ®Google Scholar
• Drach GW. Prostatitis: man's hidden infection. Urol Clin North Am 1975;2:499-520
   PubMedGoogle Scholar
• Meares EM Jr, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968;5:492-518
   PubMedGoogle Scholar
• Krieger JN, Nyberg LJ, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236-7
   PubMed Web of Science ®Google Scholar
• Schneider H, Ludwig M, Hossain HM, The 2001 Giessen Cohort Study on patients with prostatitis syndrome-an evaluation of inflammatory status and search for microorganisms 10 years after a first analysis. Andrologia 2003;35:258-62
   PubMed Web of Science ®Google Scholar
• Meares EM Jr. Acute and chronic prostatitis: diagnosis and treatment. Infect Dis Clin North Am 1987;1:855-73
   PubMedGoogle Scholar
• Nickel JC, Downey J, Clark J, Antibiotic pharmacokinetics in the inflamed prostate. J Urol 1995;153:527-9
   PubMed Web of Science ®Google Scholar
• Neal DE Jr. Treatment of acute prostatitis. In: Nickel JC, editor, Textbook of prostatitis. Isis Medical Media, Oxford, UK; 1999. p. 279-84
   Google Scholar
• Bjerklund Johansen T, Gruneberg RN, Guibert J, The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol 1998;34:457-66
   PubMed Web of Science ®Google Scholar
• Pontari MA. Inflammation and anti-inflammatory therapy in chronic prostatitis. Urology 2002;60:29-33
   PubMed Web of Science ®Google Scholar
• Naber KG, Soergel F. Antibiotic therapy rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003;35:331-5
   PubMed Web of Science ®Google Scholar
• Bulitta J, Kinzig-Schippers M, Naber CK, Limitations in the use of drug cocktails to compare the pharmacokinetics of drugs: ciprofloxacin versus levofloxacin. 40th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC). poster no. 506; 17 – 20 September 2000; Toronto, Canada
   Google Scholar
• Naber CK, Steghafner M, Kinzig-Schippers M, Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob Agents Chemother 2001;45:293-7
   PubMed Web of Science ®Google Scholar
• Cox CE, Marbury TC, Pittman WG, A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clin Ther 2002;24:223-36
   PubMed Web of Science ®Google Scholar
• Rib-X Pharmaceuticals [webpage on the internet]. New Haven, CT: Rib-X Pharm, Inc.; c2010 [updated Jan 2010, cited 2010 April 16th]. Available from: http://www.rib-x.com/pipeline/rx_3341
   Google Scholar
• Krieger JN, Egan KJ. Comprehensive evaluation and treatment of 75 men referred to chronic prostatitis clinic. Urology 1991;38:11-9
   PubMed Web of Science ®Google Scholar
• Weidner W, Ludwig M. In: Weidner W, Madsen PO, Schiefer HG, editors, Prostatitis – etiopathology, diagnosis and therapy diagnostic management of chronic prostatitis. Springer, Berlin; 1994. p. 158-74
   Google Scholar
• Schaeffer AJ, Wendel EF, Dunn JK, Prevalence and significance of prostatic inflammation. J Urol 1981;125:215-19
   PubMed Web of Science ®Google Scholar
• Nickel JC, Shoskes D, Wang Y, How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol 2006;176:119-24
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Naber KG. Prostatitis: the role of antibiotic treatment. World J Urol 2003;21:105-8
   PubMed Web of Science ®Google Scholar
• Weidner W, Jantos C, Schiefer HG, Semen parameters in men with and without proven chronic prostatitis. Arch Androl 1991;26:173-83
   PubMed Web of Science ®Google Scholar
• Stamey TA, Meares EM, Winningham G. Chronic bacterial prostatitis and the diffusion of drugs into the prostatic fluid. J Urol 1970;103:187-94
   PubMed Web of Science ®Google Scholar
• Madsen PO, Whalen PR. Interaction between antimicrobial agents and prostatic tissue extract and fluid. Infection 1978;6:75-7
   Web of Science ®Google Scholar
• Wagenlehner FM, Weidner W, Sorgel F, The role of antibiotics in chronic bacterial prostatitis. Int J Antimicrob Agents 2005;26:1-7
   PubMed Web of Science ®Google Scholar
• Sorgel F, Kinzig M, Naber KG. Physiological disposition of macrolides. In: Bryskier AJ, Butzler J-P, Neu HC, Tulkens PM, editors, Macrolides. Chemistry, pharmacology and clinical uses. Arnette Blackwell, Paris; 1993. p. 421-31
   Google Scholar
• Naber KG, Kinzig M, Sörgel F, Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid. Infection 1993;21:34-9
   PubMed Web of Science ®Google Scholar
• Kurzer E, Kaplan S. Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. Eur Urol 2002;42:163-6
   PubMed Web of Science ®Google Scholar
• Skerk V, Krhen I, Lisic M, Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis. Int J Antimicrob Agents 2004;24:188-91
   PubMed Web of Science ®Google Scholar
• Skerk V, Schonwald S, Krhen I, Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents 2003;21:457-62
   PubMed Web of Science ®Google Scholar
• Naber KJ. Antibiotic treatment of chronic bacterial prostatitis. In: Nickel JC, editor, Textbook of prostatitis, ISIS Medical Media, Oxford, UK; 1999:283-92
   Google Scholar
• Giannarini G, Tascini C, Selli C. Prulifloxacin: clinical studies of a broad-spectrum quinolone agent. Drugs 1996;51:137-60
   PubMedGoogle Scholar
• Bundrick W, Heron SP, Ray P, Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003;62:537-41
   PubMed Web of Science ®Google Scholar
• Weidner W, Ludwig M, Brahler E, Outcome of antibiotic therapy with ciprofloxacin in chronic bacterial prostatitis. Drugs 1999;58:103-6
   PubMed Web of Science ®Google Scholar
• Pfau A. The treatment of chronic bacterial prostatitis. Infection 1991;19:160-4
   Web of Science ®Google Scholar
• Nickel JC, Olson ME, Costerton JW. Rat model of experimental bacterial prostatitis. Infection 1991;19:126-30
   PubMed Web of Science ®Google Scholar
• Stamey TA, Bushby SRM, Bragonje J. The concentration of trimethoprim in prostatic fluid: non-ionic diffusion or active transport? J Infect Dis 1973;129:686-90
   Google Scholar
• Barbalias GA, Nikiforidis G, Liatsikos EN. Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol 1998;159:883-7
   PubMed Web of Science ®Google Scholar
• Shoskes DA, Zeitlin SI. Use of prostatic massage in combination with antibiotics in the treatment of chronic prostatitis. Prostate Cancer Prostatic Dis 1999;2:159-62
   PubMed Web of Science ®Google Scholar
• Boneff AN. Topical treatment of chronic prostatitis and premature ejaculation. Int Urol Nephrol 1972;4:183-6
   PubMedGoogle Scholar
• Bahk JY, Hyun JS, Lee JY, Concentration of ofloxacin in canine prostate tissue and prostate fluid after intraprostatic injection of biodegradable sustained-releasing microspheres containing ofloxacin. J Urol 2000;163:1560-4
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Hibi H, Shatoshi A, Chronic bacterial prostatitis treated with intraprostatic injection of antibiotics. Scand J Urol Nephrol 1996;30:199-201
   PubMed Web of Science ®Google Scholar
• Baert L, Leonard A. Chronic bacterial prostatitis: 10 years of experience with local antibiotics. J Urol 1988;140:755-7
   PubMed Web of Science ®Google Scholar
• Jimenez-Cruz JF, Tormo FB, Gomez JG. Treatment of chronic prostatitis: intraprostatic antibiotic injections under echography control. J Urol 1988;139:967-70
   PubMed Web of Science ®Google Scholar
• Guercini F, Pajoncini C, Bard R, Echoguided drug infiltration in chronic prostatitis: results of a multi-centre study. Arch Ital Urol Androl 2005;77:87-92
   PubMedGoogle Scholar
• Shoskes DA, Landis JR, Wang Y, ; Chronic Prostatitis Collaborative Research Network Study Group. Impact of post-ejaculatory pain in men with category III chronic prostatitis/chronic pelvic pain syndrome. J Urol 2004;172:542-7
   PubMed Web of Science ®Google Scholar
• Schaeffer AJ, Wendel EF, Dunn JK, Prevalence and significance of prostatic inflammation. J Urol 1981;125:215-19
   PubMed Web of Science ®Google Scholar
• Wenninger K, Heiman JR, Rothman I, Sickness impact of chronic nonbacterial prostatitis and its correlates. J Urol 1996;155:965-8
   PubMed Web of Science ®Google Scholar
• McNaughton-Collins M, Pontari MA, O'Leary MP, Quality of life is impaired in men with chronic prostatitis: the chronic prostatitis collaborative research network. J Gen Intern Med 2001;16:565-662
   Web of Science ®Google Scholar
• UPOINT clinical phenotype for chronic pelvic pain syndrome. [updated 2009-2010, cited 2010 April 16th]. Available from: http://www.Upointmd.com
   Google Scholar
• Litwin MS, McNaughton-Collins M, Fowler FJ, The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. J Urol 1999;162:369-75
   PubMed Web of Science ®Google Scholar
• Nickel JC, Downey J, Clark J, Levofloxacin treatment for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in men: a randomized placebo controlled multi-center trial. J Urol 2003;62:614-17
   Google Scholar
• Labro MT. Antibacterial agents – phagocytes: new concepts for old in immunomodulation. Int J Antimicrob Agents 1998;10:11-21
   PubMed Web of Science ®Google Scholar
• Bergogne-Berezin E. Interactions among antibiotics, bacteria and the human immune system: the clinical relevance of in vitro testing. J Chemother 1997;9:109-15
   PubMed Web of Science ®Google Scholar
• Kirby RS, Lowe D, Bultitude MI, Intraprostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol 1982;54:729-31
   PubMedGoogle Scholar
• Sugaya K, Nishijima S, Miyazato M, Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci Lett 2002;328:74-6
   PubMed Web of Science ®Google Scholar
• Yokoyama O, Yusup A, Oyama N, Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats. Neurourol Urodyn 2006;25:461-7
   PubMed Web of Science ®Google Scholar
• Cheah PY, Liong ML, Yuen KH, Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. J Urol 2003;169:592-6
   PubMed Web of Science ®Google Scholar
• Mehik A, Alas P, Nickel JC, Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind placebo controlled, pilot study. J Urol 2003;62:425-9
   Google Scholar
• Nickel JC, Narayan P, MacKay, J, Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 2004;171:1594-7
   PubMed Web of Science ®Google Scholar
• Alexander RB, Propert KJ, Schaeffer AJ, Chronic prostatitis collaborative research network: ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med 2004;141:581-9
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu X, Liu J, Effects of a 6-month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. World J Urol 2010. [Epub ahead of print]
   Web of Science ®Google Scholar
• Nickel JC, Krieger JN, McNaughton-Collins M, Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med 2008;359:2663-73
   PubMed Web of Science ®Google Scholar
• Rugendorff EW, Weidner W, Ebeling L. Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol 1993;71:433-8
   PubMedGoogle Scholar
• Wagenlehner FM, Schneider H, Ludwig M, A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol 2009;56:544-51
   PubMed Web of Science ®Google Scholar
• Shoskes DA. Use of the bioflavonoid quercetin in patients with longstanding chronic prostatitis. J Am Neutraceutic Assoc 1999;2:18-21
   Google Scholar
• Shoskes DA, Zeitlin SI, Shahed A, Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo control trial. Urol 1999;54:960-3
   PubMed Web of Science ®Google Scholar
• Shahed AR, Shoskes DA. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome: correlation with gram positive bacterial growth and treatment response. J Androl 2000;21:669-75
   PubMedGoogle Scholar
• Shahed AR, Shoskes DA. Correlation of beta-endorphin and prostaglandin e2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response. J Urol 2001;166:1738-41
   PubMed Web of Science ®Google Scholar
• Reissigl AE, Djavan B, Pointner J, Chronic prostatitis/chronic pelvic pain syndrome recurrence after initial effective phytotherapeutic treatment. J Urol 2005;173:S30
   Web of Science ®Google Scholar
• Canale D, Turchi P, Girogi PM, Treatment of abacterial prostato-vasculitis with nimesulide. Drugs 1993;46:147-50
   PubMedGoogle Scholar
• Dimitrakov JD, Tchitalov J, Dikov D. Efficacy and safety of corticosteroids in the treatment of CP/CPPS: a randomized double blind placebo controlled trial. J Urol 2004;171:61
   PubMed Web of Science ®Google Scholar
• Nickel JC, Pontari M, Moon T, A randomized, placebo controlled multi-center study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic non-bacterial prostatitis. J Urol 2003;169:1045
   Web of Science ®Google Scholar
• Nickel JC, Forrest JB, Tomera K, Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. J Urol 2005;173:1252-5
   PubMed Web of Science ®Google Scholar
• Nickel JC. 5-Alpha reductase therapy for chronic prostatitis. In: Nickel JC, editors, Textbook of prostatitis, Isis Medical Media, Oxford, UK; 1999. p. 333-7
   Google Scholar
• Leskinen M, Lukkarinen O, Marttilla T. Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double-blind, placebo controlled, pilot study. Urology 1999;53:502-5
   PubMed Web of Science ®Google Scholar
• Nickel JC, Downey J, Pontari MA, A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIa chronic nonbacterial prostatitis). BJU Int 2004;93:991-5
   PubMed Web of Science ®Google Scholar
• De Rose AF, Gallo F, Giglio M, Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial. Urology 2004;63:13-6
   PubMed Web of Science ®Google Scholar
• Pontari M, Krieger JN, Litwin MS, A randomized placebo-controlled multicenter trial of pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome. J Urol 2009;181:123
   Google Scholar
• Schaeffer AJ. Etiology and management of chronic pelvic pain syndrome in men. Urology 2004;63:75-84
   PubMed Web of Science ®Google Scholar
• Anderson RU. Treatment of prostatodynia (pelvic floor myalgia or chronic non-inflammatory pelvic pain syndrome). In: Nickel JC, editor, Textbook of prostatitis, ISIS Medical Media, Oxford, UK; 1999. p. 357-64
   Google Scholar
• Dworkin RH, O'Connor AB, Audette J, Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3-14
   PubMed Web of Science ®Google Scholar
• Anderson RU, Wise D, Sawyer T, Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. J Urol 2005;174:155-60
   PubMed Web of Science ®Google Scholar
• Anderson RU, Wise D, Sawyer T, Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: improvement after trigger point release and paradoxical relaxation training. J Urol 2006;176:1534-8; discussion 1538-9
   PubMed Web of Science ®Google Scholar
• FitzGerald MP, Anderson RU, Potts J, Urological pelvic pain collaborative research network. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol 2009;182:570-80
   PubMed Web of Science ®Google Scholar
• Nickel JC, Downey J, Ardern D, Failure of a monotherapy strategy for difficult chronic prostatitis/chronic pelvic pain syndrome. J Urol 2004;172:551-4
   PubMed Web of Science ®Google Scholar
• Shoskes DA, Hakim L, Ghoniem G, Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. J Urol 2003;169:1406-10
   PubMed Web of Science ®Google Scholar
• Tuğcu V, Tasci AI, Fazlioglu A, A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS). Eur Urol 2007;51:1113-7
   PubMed Web of Science ®Google Scholar
• Shoskes DA, Nickel JC, Rackley RR, Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis 2009;12:177-83
   PubMed Web of Science ®Google Scholar
• Shoskes DA, Nickel JC, Dolinga R, Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology 2009;73:538-42; discussion 542-3
   PubMed Web of Science ®Google Scholar
• Nickel JC, Shoskes, D, Irvine-Bird, K, Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome: a key to classification and potentially improved management. J Urol 2009;182:155-60
   PubMed Web of Science ®Google Scholar
• Hedelin HH. Evaluation of a modification of the UPOINT clinical phenotype system for the chronic pelvic pain syndrome. Scand J Urol Nephrol 2009;43:373-6
   PubMed Web of Science ®Google Scholar
• Shoskes DA, Nickel JC, Kattan MW. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology 2010. [Epub ahead of print]
   Google Scholar
• Sandhu JS. Prostate cancer and chronic prostatitis. Curr Urol Rep 2008;9:328-32
   PubMedGoogle Scholar
• Stopiglia RM, Ferreira U, Silva MM Jr, Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial. J Urol 2010;183:940-4
   PubMed Web of Science ®Google Scholar
• Shoskes DA. Chronic prostatitis/chronic pelvic pain syndrome: the status Quo is not good enough (but it can). UroToday Int J 2010; In press
   Google Scholar